31 July 2018
Visiongain has launched a new pharma report Diabetic Neuropathy Treatment: World Market 2018-2028: Analysis and Forecasts by Disorder (Peripheral, Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies
Diabetic neuropathy is a chronic disorder characterised by nerve damage caused due to prolonged elevated levels of blood glucose. Diabetic neuropathy may be caused by both type 1 and type 2 diabetes. It affects sensory, motor and autonomic nerves of the body. Treatment of diabetic neuropathy depends upon the type of nerve damage.
The lead analyst of the report commented “Increase in the incidence of diabetes is the major factor increasing the size of the diabetic neuropathy treatment market. Rises in obesity, unhealthy diets, consumption of alcohol & smoking and sedentary lifestyles, along with an ageing population are all factors that in combination are anticipated to increase the diabetic neuropathy market. Furthermore, approvals for drugs associated with diabetic neuropathy control by the FDA is anticipated to further escalate the market growth.
However, side effects of diabetic neuropathy drugs and rising cost of drugs is estimated to hinder the market growth. Ongoing, research and development associated with diabetic neuropathy treatment is anticipated to create new opportunities in the forecast period.
Leading companies featured in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc., Lupin Limited, Glenmark Pharmaceuticals Limited, Depomed, Inc., Astellas Pharma Inc., and Pfizer Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
02 September 2021
As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.
24 August 2021
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
24 August 2021
Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.